133 related articles for article (PubMed ID: 1553049)
1. [The pre- and postoperative and follow-up use of the tumor markers MCA, CA-125 and CA-19-9].
Zanon C; Alluminio P; Margarita V; Sottimano C; Giuliani F; Neri G; Ballario F
Minerva Chir; 1992 Jan; 47(1-2):27-30. PubMed ID: 1553049
[TBL] [Abstract][Full Text] [Related]
2. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
[TBL] [Abstract][Full Text] [Related]
3. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
4. [Tumor markers in the early diagnosis of recurrence in gynecologic neoplasms: combined determination of CA-125, CA 15-3, CA 72.4, SCC, 90 K].
Garzetti GC; Di Lauro RM; Ciavattini A; Pallotta MR; Marchegiani F; Valensise H; Tranquilli AL; Arduini D; Romanini C
Ann Ostet Ginecol Med Perinat; 1991; 112(5):320-3. PubMed ID: 1817444
[TBL] [Abstract][Full Text] [Related]
5. [Pre- and post-therapeutic serum concentrations of mucin-like carcinoma-associated antigen in patients with breast cancer].
Fuith LC; Artner-Dworzak E; Schröcksnadel H; Müller-Holzner E; Daxenbichler G; Heim K
Gynakol Rundsch; 1989; 29 Suppl 2():397-9. PubMed ID: 2613061
[No Abstract] [Full Text] [Related]
6. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
8. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
[TBL] [Abstract][Full Text] [Related]
9. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of MCA and CA 15-3 in tissue and in serum of patients with breast carcinoma: preliminary results.
Reale G; Giovagnoli MR; Vecchione A; Cosentino L; Benci F; Manna A; Marchei G; Vittori I; Frati L
J Nucl Med Allied Sci; 1990; 34(4 Suppl):53. PubMed ID: 2092150
[No Abstract] [Full Text] [Related]
12. [Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast].
Bumma C; Bramardi AM; Lauria G; Arese P; Marchetti G
J Nucl Med Allied Sci; 1990; 34(4 Suppl):29-32. PubMed ID: 2092137
[No Abstract] [Full Text] [Related]
13. [Mucinous carcinoma-associated antigen (MCA) in ovarian cancer].
Hanzal E; Kölbl H; Gitsch G; Bieglmayer C
Gynakol Rundsch; 1990; 30 Suppl 1():68-70. PubMed ID: 2079303
[No Abstract] [Full Text] [Related]
14. [Preliminary experience with BCM-IMx as a pretreatment marker of breast tumors].
Fernández Llana B; Fernández Fernández M; Suárez B; Allende MT
Rev Clin Esp; 1992 Mar; 190(4):209. PubMed ID: 1589619
[No Abstract] [Full Text] [Related]
15. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
16. [Tumor marker combination versus second-look operation in ovarian cancer].
Lahousen M; Stettner H; Pürstner P; Pickel H
Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of a new tumor marker (M.C.A.) in the breast cancer follow-up.
Cappellari A; Bagarella M; Corradi G
Boll Ist Sieroter Milan; 1990; 69(1):315-8. PubMed ID: 2102115
[TBL] [Abstract][Full Text] [Related]
18. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
19. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
